MedTrace Logo

Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)

NCT00002027 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-06-24

No results posted yet for this study

Summary

To evaluate the safety and efficacy of diclazuril capsules compared with placebo capsules as treatment of cryptosporidial related diarrhea in AIDS patients. Treatment efficacy will be based on the drug's clinical results and on its anti-protozoan effects. Safety will be assessed by the occurrence of side effects as reported by patients at their visits and by frequent monitoring of hematology, biochemistries, and urinalysis.

Conditions

  • Cryptosporidiosis
  • HIV Infections

Interventions

DRUG

Diclazuril

Sponsors & Collaborators

  • Janssen, LP

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002027 on ClinicalTrials.gov